These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

358 related items for PubMed ID: 15814635

  • 1. Opposite roles of human pancreatitis-associated protein and REG1A expression in hepatocellular carcinoma: association of pancreatitis-associated protein expression with low-stage hepatocellular carcinoma, beta-catenin mutation, and favorable prognosis.
    Yuan RH, Jeng YM, Chen HL, Hsieh FJ, Yang CY, Lee PH, Hsu HC.
    Clin Cancer Res; 2005 Apr 01; 11(7):2568-75. PubMed ID: 15814635
    [Abstract] [Full Text] [Related]

  • 2. Expression of mutant nuclear beta-catenin correlates with non-invasive hepatocellular carcinoma, absence of portal vein spread, and good prognosis.
    Mao TL, Chu JS, Jeng YM, Lai PL, Hsu HC.
    J Pathol; 2001 Jan 01; 193(1):95-101. PubMed ID: 11169521
    [Abstract] [Full Text] [Related]

  • 3. Overexpression of regenerating islet-derived 1 alpha and 3 alpha genes in human primary liver tumors with beta-catenin mutations.
    Cavard C, Terris B, Grimber G, Christa L, Audard V, Radenen-Bussiere B, Simon MT, Renard CA, Buendia MA, Perret C.
    Oncogene; 2006 Jan 26; 25(4):599-608. PubMed ID: 16314847
    [Abstract] [Full Text] [Related]

  • 4. ASPM is a novel marker for vascular invasion, early recurrence, and poor prognosis of hepatocellular carcinoma.
    Lin SY, Pan HW, Liu SH, Jeng YM, Hu FC, Peng SY, Lai PL, Hsu HC.
    Clin Cancer Res; 2008 Aug 01; 14(15):4814-20. PubMed ID: 18676753
    [Abstract] [Full Text] [Related]

  • 5. Altered expression of E-cadherin in hepatocellular carcinoma: correlations with genetic alterations, beta-catenin expression, and clinical features.
    Wei Y, Van Nhieu JT, Prigent S, Srivatanakul P, Tiollais P, Buendia MA.
    Hepatology; 2002 Sep 01; 36(3):692-701. PubMed ID: 12198663
    [Abstract] [Full Text] [Related]

  • 6. Overexpression of osteopontin is associated with intrahepatic metastasis, early recurrence, and poorer prognosis of surgically resected hepatocellular carcinoma.
    Pan HW, Ou YH, Peng SY, Liu SH, Lai PL, Lee PH, Sheu JC, Chen CL, Hsu HC.
    Cancer; 2003 Jul 01; 98(1):119-27. PubMed ID: 12833464
    [Abstract] [Full Text] [Related]

  • 7. Stathmin overexpression cooperates with p53 mutation and osteopontin overexpression, and is associated with tumour progression, early recurrence, and poor prognosis in hepatocellular carcinoma.
    Yuan RH, Jeng YM, Chen HL, Lai PL, Pan HW, Hsieh FJ, Lin CY, Lee PH, Hsu HC.
    J Pathol; 2006 Aug 01; 209(4):549-58. PubMed ID: 16739096
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Beta-catenin and cyclin D1 expression in human hepatocellular carcinoma.
    Ueta T, Ikeguchi M, Hirooka Y, Kaibara N, Terada T.
    Oncol Rep; 2002 Aug 01; 9(6):1197-203. PubMed ID: 12375019
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Overexpression of pituitary tumor-transforming gene-1 in hepatocellular carcinoma.
    Su MC, Hsu HC, Liu YJ, Jeng YM.
    Hepatogastroenterology; 2006 Aug 01; 53(68):262-5. PubMed ID: 16608036
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Beta-catenin accumulation in the progression of human hepatocarcinogenesis correlates with loss of E-cadherin and accumulation of p53, but not with expression of conventional WNT-1 target genes.
    Prange W, Breuhahn K, Fischer F, Zilkens C, Pietsch T, Petmecky K, Eilers R, Dienes HP, Schirmacher P.
    J Pathol; 2003 Oct 01; 201(2):250-9. PubMed ID: 14517842
    [Abstract] [Full Text] [Related]

  • 16. Cloning and expression of a developmentally regulated transcript MXR7 in hepatocellular carcinoma: biological significance and temporospatial distribution.
    Hsu HC, Cheng W, Lai PL.
    Cancer Res; 1997 Nov 15; 57(22):5179-84. PubMed ID: 9371521
    [Abstract] [Full Text] [Related]

  • 17. Comparison of the expression of beta-catenin in hepatocellular carcinoma in areas with high and low levels of exposure to aflatoxin B1.
    Chen Ban K, Singh H, Krishnan R, Fong Seow H.
    J Surg Oncol; 2004 Jun 01; 86(3):157-63. PubMed ID: 15170655
    [Abstract] [Full Text] [Related]

  • 18. Mutations of beta-catenin and AXIN I genes are a late event in human hepatocellular carcinogenesis.
    Park JY, Park WS, Nam SW, Kim SY, Lee SH, Yoo NJ, Lee JY, Park CK.
    Liver Int; 2005 Feb 01; 25(1):70-6. PubMed ID: 15698401
    [Abstract] [Full Text] [Related]

  • 19. Mutational spectrum of beta-catenin, AXIN1, and AXIN2 in hepatocellular carcinomas and hepatoblastomas.
    Taniguchi K, Roberts LR, Aderca IN, Dong X, Qian C, Murphy LM, Nagorney DM, Burgart LJ, Roche PC, Smith DI, Ross JA, Liu W.
    Oncogene; 2002 Jul 18; 21(31):4863-71. PubMed ID: 12101426
    [Abstract] [Full Text] [Related]

  • 20. Concurrent evaluation of p53, beta-catenin, and alpha-fetoprotein expression in human hepatocellular carcinoma.
    Torbenson M, Kannangai R, Abraham S, Sahin F, Choti M, Wang J.
    Am J Clin Pathol; 2004 Sep 18; 122(3):377-82. PubMed ID: 15362367
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.